Skip to main content
Top

Open Access 09-06-2024 | Systematic Review

Association of Drug–Disease Interactions with Mortality or Readmission in Hospitalised Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis

Authors: Joshua M. Inglis, Gillian Caughey, Tilenka Thynne, Kate Brotherton, Danny Liew, Arduino A. Mangoni, Sepehr Shakib

Published in: Drugs - Real World Outcomes

Login to get access

Abstract

Background and Objective

Multimorbidity is common in hospitalised adults who are at increased risk of inappropriate prescribing including drug–disease interactions. These interactions occur when a medicine being used to treat one condition exacerbates a concurrent medical condition and may lead to adverse health outcomes. The aim of this review was to examine the association between drug–disease interactions and the risk of mortality and readmission in hospitalised middle-aged and older adults.

Methods

A systematic review was conducted on drug–disease interactions in hospitalised middle-aged (45–64 years) and older adults (≥65 years). The study protocol was prospectively registered with PROSPERO (Registration Number: CRD42022341998). Drug–disease interactions were defined as a medicine being used to treat one condition with the potential to exacerbate a concurrent medical condition or that were inappropriate based on a comorbid medical condition. Both observational and interventional studies were included. The outcomes of interest were mortality and readmissions. The databases searched included MEDLINE, CINAHL, EMBASE, Web of Science, SCOPUS and the Cochrane Library from inception to 12 July, 2022. A meta-analysis was performed to pool risk estimates using the random-effects model.

Results

A total of 563 studies were identified and four met the inclusion criteria. All were observational studies in older adults, with no studies identified in middle-aged adults. Most of the studies were at risk of bias because of an inadequate adjustment for covariates and a lack of clarity around individuals lost to follow-up. There were various definitions of drug–disease interactions within these four studies. Two studies assessed drugs that were contraindicated based on renal function, one assessed an individual drug–disease combination, and one was based on the clinical judgement of a pharmacist. There were two studies that showed an association between drug–disease interactions and the outcomes of interest. One reported that the use of diltiazem in patients with heart failure was associated with an increased risk of readmissions. The second reported that the use of medicines contraindicated according to renal function were associated with increased risk of all-cause mortality and a composite of mortality and readmission. Three of the studies (total study population = 5705) were amenable to a meta-analysis, which showed no significant association between drug–disease interactions and readmissions (odds ratio = 1.0, 95% confidence interval 0.80–1.38).

Conclusions

Few studies were identified examining the risk of drug–disease interactions and mortality and readmission in hospitalised adults. Most of the identified studies were at risk of bias. There is no universal accepted definition of drug–disease interactions in the literature. Further studies are needed to develop a standardised and accepted definition of these interactions to guide further research in this area.
Appendix
Available only for authorised users
Literature
1.
go back to reference Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430–9.PubMedCrossRef Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430–9.PubMedCrossRef
2.
go back to reference Koné Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The increasing burden and complexity of multimorbidity. BMC Public Health. 2015;15:1–11.CrossRef Koné Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. The increasing burden and complexity of multimorbidity. BMC Public Health. 2015;15:1–11.CrossRef
3.
go back to reference Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseased. J Comorbidity. 2013;3:4–9.CrossRef Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseased. J Comorbidity. 2013;3:4–9.CrossRef
4.
go back to reference Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022;12: e055551.PubMedPubMedCentralCrossRef Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022;12: e055551.PubMedPubMedCentralCrossRef
5.
go back to reference Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, et al. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999;6:1232–42.PubMedCrossRef Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, et al. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med. 1999;6:1232–42.PubMedCrossRef
6.
go back to reference Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc. 2001;49:277–83.PubMedCrossRef Giron MS, Wang HX, Bernsten C, Thorslund M, Winblad B, Fastbom J. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc. 2001;49:277–83.PubMedCrossRef
7.
go back to reference Hanlon JT, Schmader KE, Boult C, Artz MB, Gross CR, Fillenbaum GG, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc. 2002;50:26–34.PubMedCrossRef Hanlon JT, Schmader KE, Boult C, Artz MB, Gross CR, Fillenbaum GG, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc. 2002;50:26–34.PubMedCrossRef
8.
go back to reference Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20:13.PubMedPubMedCentralCrossRef Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20:13.PubMedPubMedCentralCrossRef
9.
go back to reference Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, et al. Multidisciplinary Consensus Panel. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28:1133–43.PubMedCrossRef Lindblad CI, Hanlon JT, Gross CR, Sloane RJ, Pieper CF, Hajjar ER, et al. Multidisciplinary Consensus Panel. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28:1133–43.PubMedCrossRef
10.
go back to reference Caughey GE, Barratt JD, Shakib S. Medication use and potentially high-risk prescribing in older patients hospitalized for diabetes. Diabet Med. 2017;34:432–9.PubMedCrossRef Caughey GE, Barratt JD, Shakib S. Medication use and potentially high-risk prescribing in older patients hospitalized for diabetes. Diabet Med. 2017;34:432–9.PubMedCrossRef
11.
go back to reference Caughey GE, Roughead EE, Shakib S. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing. 2010;39:488–94.PubMedCrossRef Caughey GE, Roughead EE, Shakib S. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants. Age Ageing. 2010;39:488–94.PubMedCrossRef
12.
go back to reference Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Comorbidity and potential treatment conflicts in the elderly with heart failure. Drugs Aging. 2011;28:1–7.CrossRef Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Comorbidity and potential treatment conflicts in the elderly with heart failure. Drugs Aging. 2011;28:1–7.CrossRef
13.
go back to reference Caughey GE, Roughead EE, Vitry AI. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87:385–93.PubMedCrossRef Caughey GE, Roughead EE, Vitry AI. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87:385–93.PubMedCrossRef
14.
go back to reference Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36:3009–14.PubMedPubMedCentralCrossRef Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36:3009–14.PubMedPubMedCentralCrossRef
15.
go back to reference Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–40.PubMedCrossRef Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–40.PubMedCrossRef
16.
go back to reference Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA. 2011;306:2670–2.PubMedCrossRef Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA. 2011;306:2670–2.PubMedCrossRef
17.
go back to reference Fanning L, Ilomäki J, Bell JS, Dārziņš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol. 2017;73:1427–36.PubMedCrossRef Fanning L, Ilomäki J, Bell JS, Dārziņš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol. 2017;73:1427–36.PubMedCrossRef
18.
go back to reference Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ. 2015;351: h4984.PubMedPubMedCentralCrossRef Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ. 2015;351: h4984.PubMedPubMedCentralCrossRef
19.
go back to reference Caughey GE, Inacio MC, Bell JS, Vitry AI, Shakib S. Inclusion of older people reflective of real-world clinical practice in cardiovascular drug trials. J Am Heart Assoc. 2020;9: e016936.PubMedPubMedCentralCrossRef Caughey GE, Inacio MC, Bell JS, Vitry AI, Shakib S. Inclusion of older people reflective of real-world clinical practice in cardiovascular drug trials. J Am Heart Assoc. 2020;9: e016936.PubMedPubMedCentralCrossRef
20.
go back to reference Tinetti ME, McAvay G, Trentalange M, et al. Association between guideline recommended drugs and death in older adults with multiple chronic conditions. BMJ. 2015;351: h4984.PubMedPubMedCentralCrossRef Tinetti ME, McAvay G, Trentalange M, et al. Association between guideline recommended drugs and death in older adults with multiple chronic conditions. BMJ. 2015;351: h4984.PubMedPubMedCentralCrossRef
21.
go back to reference Peeters G, Tett SE, Hollingworth SA, et al. Associations of guideline recommended medications for acute coronary syndromes with fall-related hospitalizations and cardiovascular events. J Gerontol A Biol Sci Med Sci. 2017;72:259–65.PubMedCrossRef Peeters G, Tett SE, Hollingworth SA, et al. Associations of guideline recommended medications for acute coronary syndromes with fall-related hospitalizations and cardiovascular events. J Gerontol A Biol Sci Med Sci. 2017;72:259–65.PubMedCrossRef
22.
go back to reference Sheppard JP, Koshiaris C, Stevens R, Lay-Flurrie S, Banerjee A, Bellows BK, et al. The association between antihypertensive treatment and serious adverse events by age and frailty: a cohort study. PLoS Med. 2023;20: e1004223.PubMedPubMedCentralCrossRef Sheppard JP, Koshiaris C, Stevens R, Lay-Flurrie S, Banerjee A, Bellows BK, et al. The association between antihypertensive treatment and serious adverse events by age and frailty: a cohort study. PLoS Med. 2023;20: e1004223.PubMedPubMedCentralCrossRef
23.
go back to reference Kremer KM, Braisch U, Rothenbacher D, Denkinger M, Dallmeier D. Systolic blood pressure and mortality in community-dwelling older adults: frailty as an effect modifier. Hypertension. 2022;79:24–32.PubMedCrossRef Kremer KM, Braisch U, Rothenbacher D, Denkinger M, Dallmeier D. Systolic blood pressure and mortality in community-dwelling older adults: frailty as an effect modifier. Hypertension. 2022;79:24–32.PubMedCrossRef
24.
go back to reference Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, et al. Association between claims-defined frailty and outcomes following 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention: findings from the EXTEND-DAPT Study. J Am Heart Assoc. 2023;2: e029588.CrossRef Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, et al. Association between claims-defined frailty and outcomes following 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention: findings from the EXTEND-DAPT Study. J Am Heart Assoc. 2023;2: e029588.CrossRef
25.
go back to reference Mondal A, Li A, Edusa S, Gogineni A, Karipineni S, Abdelhafez S, et al. Does statin use in frail patients provide survival benefits? Insights from a meta-analysis. Curr Probl Cardiol. 2024;49: 102038.PubMedCrossRef Mondal A, Li A, Edusa S, Gogineni A, Karipineni S, Abdelhafez S, et al. Does statin use in frail patients provide survival benefits? Insights from a meta-analysis. Curr Probl Cardiol. 2024;49: 102038.PubMedCrossRef
26.
go back to reference Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.PubMedCrossRef Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.PubMedCrossRef
27.
go back to reference Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87:4150–72.PubMedCrossRef Mekonnen AB, Redley B, de Courten B, Manias E. Potentially inappropriate prescribing and its associations with health-related and system-related outcomes in hospitalised older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87:4150–72.PubMedCrossRef
28.
go back to reference Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350: h949.PubMedPubMedCentralCrossRef Dumbreck S, Flynn A, Nairn M, Wilson M, Treweek S, Mercer SW, et al. Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350: h949.PubMedPubMedCentralCrossRef
29.
go back to reference Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.PubMedPubMedCentralCrossRef Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.PubMedPubMedCentralCrossRef
30.
32.
go back to reference Sirois C, Laroche ML, Guénette L, Kröger E, Cooper D, Émond V. Polypharmacy in multimorbid older adults: protocol for a systematic review. Syst Rev. 2017;6:104.PubMedPubMedCentralCrossRef Sirois C, Laroche ML, Guénette L, Kröger E, Cooper D, Émond V. Polypharmacy in multimorbid older adults: protocol for a systematic review. Syst Rev. 2017;6:104.PubMedPubMedCentralCrossRef
34.
go back to reference Sirois C, Domingues NS, Laroche ML, Zongo A, Lunghi C, Guénette L, et al. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy (Basel). 2019;7:126.PubMedPubMedCentralCrossRef Sirois C, Domingues NS, Laroche ML, Zongo A, Lunghi C, Guénette L, et al. Polypharmacy definitions for multimorbid older adults need stronger foundations to guide research, clinical practice and public health. Pharmacy (Basel). 2019;7:126.PubMedPubMedCentralCrossRef
36.
go back to reference Holger S, Suzanne H, Gordon G, Elie AA, Faruque A. The GRADE approach and Bradford Hill’’s criteria for causation. J Epidemiol Community Health. 2011;65:392.CrossRef Holger S, Suzanne H, Gordon G, Elie AA, Faruque A. The GRADE approach and Bradford Hill’’s criteria for causation. J Epidemiol Community Health. 2011;65:392.CrossRef
37.
go back to reference Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Ghersi D, et al. GRADE: assessing the quality of evidence in environmental and occupational health. Environ Int. 2016;92–93:611–6.PubMedPubMedCentralCrossRef Morgan RL, Thayer KA, Bero L, Bruce N, Falck-Ytter Y, Ghersi D, et al. GRADE: assessing the quality of evidence in environmental and occupational health. Environ Int. 2016;92–93:611–6.PubMedPubMedCentralCrossRef
38.
go back to reference Delgado J, Jones L, Bradley MC, Allan LM, Ballard C, Clare L, et al. Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing. 2021;50:457–64.PubMedCrossRef Delgado J, Jones L, Bradley MC, Allan LM, Ballard C, Clare L, et al. Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing. 2021;50:457–64.PubMedCrossRef
39.
go back to reference Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937–44.PubMedCrossRef Wessinger S, Kaplan M, Choi L, Williams M, Lau C, Sharp L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937–44.PubMedCrossRef
40.
go back to reference Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322–9.PubMedPubMedCentralCrossRef Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009;120:2322–9.PubMedPubMedCentralCrossRef
41.
go back to reference Gigante A, Proietti M, Petrillo E, Mannucci PM, Nobili A, Muscaritoli M. Renal function, cardiovascular diseases, appropriateness of drug prescription and outcomes in hospitalized older patients. Drugs Aging. 2021;38:1097–105.PubMedCrossRef Gigante A, Proietti M, Petrillo E, Mannucci PM, Nobili A, Muscaritoli M. Renal function, cardiovascular diseases, appropriateness of drug prescription and outcomes in hospitalized older patients. Drugs Aging. 2021;38:1097–105.PubMedCrossRef
43.
go back to reference Bingham JM, Baugham L, Hilaneh A, Tranchina K, Arku D, Eckert B, et al. Assessing the impact of an advanced clinical decision support system on medication safety and hospital readmissions in an innovative transitional care model: a pilot study. J Clin Med. 2022;11:2070.PubMedPubMedCentralCrossRef Bingham JM, Baugham L, Hilaneh A, Tranchina K, Arku D, Eckert B, et al. Assessing the impact of an advanced clinical decision support system on medication safety and hospital readmissions in an innovative transitional care model: a pilot study. J Clin Med. 2022;11:2070.PubMedPubMedCentralCrossRef
44.
go back to reference O’Shaughnessy M, Allen N, O’Regan J, Payne-Danson E, Mentre L, Davin D, et al. Agreement between renal prescribing references and determination of prescribing appropriateness in hospitalized patients with chronic kidney disease. QJM. 2017;110:623–8.PubMedPubMedCentralCrossRef O’Shaughnessy M, Allen N, O’Regan J, Payne-Danson E, Mentre L, Davin D, et al. Agreement between renal prescribing references and determination of prescribing appropriateness in hospitalized patients with chronic kidney disease. QJM. 2017;110:623–8.PubMedPubMedCentralCrossRef
45.
go back to reference Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics (Basel). 2020;5:85.PubMedPubMedCentralCrossRef Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics (Basel). 2020;5:85.PubMedPubMedCentralCrossRef
46.
go back to reference Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588–95.PubMedPubMedCentralCrossRef Tinetti ME, Han L, Lee DS, McAvay GJ, Peduzzi P, Gross CP, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174:588–95.PubMedPubMedCentralCrossRef
47.
go back to reference Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Osteoporitic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–51.PubMedCrossRef Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, et al. Osteoporitic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167:1246–51.PubMedCrossRef
48.
go back to reference Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Candian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–94.PubMedCrossRef Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC, et al. Candian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188–94.PubMedCrossRef
49.
go back to reference Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust. 2006;185:549–57.PubMedCrossRef Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, Hawkes AL. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust. 2006;185:549–57.PubMedCrossRef
50.
go back to reference Roughead EE, Barratt JD, Ramsay E, Pratt N, Ryan P, Peck R, et al. The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting. Circ Heart Fail. 2009;2:424–8.PubMedCrossRef Roughead EE, Barratt JD, Ramsay E, Pratt N, Ryan P, Peck R, et al. The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting. Circ Heart Fail. 2009;2:424–8.PubMedCrossRef
51.
go back to reference Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–50.PubMedCrossRef
53.
go back to reference Boland P, Pavlick AC, Weber J, Sandigursky S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer. 2020;8: e000356.PubMedPubMedCentralCrossRef Boland P, Pavlick AC, Weber J, Sandigursky S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer. 2020;8: e000356.PubMedPubMedCentralCrossRef
57.
go back to reference van Tongeren JMZ, Harkes-Idzinga SF, van der Sijs H, Atiqi R, van den Bemt BJF, Draijer LW, et al. The development of practice recommendations for drug-disease interactions by literature review and expert opinion. Front Pharmacol. 2020;11:707.PubMedPubMedCentralCrossRef van Tongeren JMZ, Harkes-Idzinga SF, van der Sijs H, Atiqi R, van den Bemt BJF, Draijer LW, et al. The development of practice recommendations for drug-disease interactions by literature review and expert opinion. Front Pharmacol. 2020;11:707.PubMedPubMedCentralCrossRef
58.
go back to reference Tan ECK, Sluggett JK, Johnell K, Onder G, Elseviers M, Morin L, et al. Research priorities for optimizing geriatric pharmacotherapy: an international consensus. J Am Med Dir Assoc. 2018;19:193–9.PubMedCrossRef Tan ECK, Sluggett JK, Johnell K, Onder G, Elseviers M, Morin L, et al. Research priorities for optimizing geriatric pharmacotherapy: an international consensus. J Am Med Dir Assoc. 2018;19:193–9.PubMedCrossRef
59.
go back to reference Kwoh CK, Ibrahim SA. Rheumatology patient and physician concordance with respect to important health and symptom status outcomes. Arthritis Rheum. 2001;45:372–7.PubMedCrossRef Kwoh CK, Ibrahim SA. Rheumatology patient and physician concordance with respect to important health and symptom status outcomes. Arthritis Rheum. 2001;45:372–7.PubMedCrossRef
60.
go back to reference Fahmi A, Wong D, Walker L, Buchan I, Pirmohamed M, Sharma A, et al. Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: large variability in risks of adverse drug related and emergency hospital admissions. PLoS One. 2023;18: e0281466.PubMedPubMedCentralCrossRef Fahmi A, Wong D, Walker L, Buchan I, Pirmohamed M, Sharma A, et al. Combinations of medicines in patients with polypharmacy aged 65–100 in primary care: large variability in risks of adverse drug related and emergency hospital admissions. PLoS One. 2023;18: e0281466.PubMedPubMedCentralCrossRef
61.
go back to reference Heaf J, Heiro M, Petersons A, Vernere B, Povlsen JV, Sørensen AB, et al. First-year mortality in incident dialysis patients: results of the Peridialysis study. BMC Nephrol. 2022;23:229.PubMedPubMedCentralCrossRef Heaf J, Heiro M, Petersons A, Vernere B, Povlsen JV, Sørensen AB, et al. First-year mortality in incident dialysis patients: results of the Peridialysis study. BMC Nephrol. 2022;23:229.PubMedPubMedCentralCrossRef
62.
go back to reference Toson B, Harvey LA, Close JC. New ICD-10 version of the multipurpose Australian comorbidity scoring system outperformed Charlson and Elixhauser comorbidities in an older population. J Clin Epidemiol. 2016;79:62–9.PubMedCrossRef Toson B, Harvey LA, Close JC. New ICD-10 version of the multipurpose Australian comorbidity scoring system outperformed Charlson and Elixhauser comorbidities in an older population. J Clin Epidemiol. 2016;79:62–9.PubMedCrossRef
63.
go back to reference Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237–48.PubMedCrossRef Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237–48.PubMedCrossRef
64.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
65.
66.
go back to reference Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174:613–20.PubMedCrossRef Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174:613–20.PubMedCrossRef
67.
go back to reference Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291–303.PubMedCrossRef Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291–303.PubMedCrossRef
Metadata
Title
Association of Drug–Disease Interactions with Mortality or Readmission in Hospitalised Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis
Authors
Joshua M. Inglis
Gillian Caughey
Tilenka Thynne
Kate Brotherton
Danny Liew
Arduino A. Mangoni
Sepehr Shakib
Publication date
09-06-2024
Publisher
Springer International Publishing
Published in
Drugs - Real World Outcomes
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI
https://doi.org/10.1007/s40801-024-00432-3